Nuvation Bio Inc. announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific for IBTROZI (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a supplement to the IBTROZI New Drug Application held by Nuvation Bio and is now complete. Thermo Fisher Scientific will now manufacture drug product for Nuvation Bio in the United States.
Move by Nuvation Bio further ensures critical drug supply for patients and providers.
